NO20032614L - Farmasöytisk sammensetning som har forbedret absorberbarhet - Google Patents
Farmasöytisk sammensetning som har forbedret absorberbarhetInfo
- Publication number
- NO20032614L NO20032614L NO20032614A NO20032614A NO20032614L NO 20032614 L NO20032614 L NO 20032614L NO 20032614 A NO20032614 A NO 20032614A NO 20032614 A NO20032614 A NO 20032614A NO 20032614 L NO20032614 L NO 20032614L
- Authority
- NO
- Norway
- Prior art keywords
- pharmaceutical composition
- improved absorbability
- absorbability
- improved
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000375608 | 2000-12-11 | ||
| PCT/JP2001/010827 WO2002048142A1 (fr) | 2000-12-11 | 2001-12-11 | Compositions medicamenteuses presentant une meilleure absorbabilite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20032614D0 NO20032614D0 (no) | 2003-06-10 |
| NO20032614L true NO20032614L (no) | 2003-08-05 |
Family
ID=18844596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20032614A NO20032614L (no) | 2000-12-11 | 2003-06-10 | Farmasöytisk sammensetning som har forbedret absorberbarhet |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040053972A1 (no) |
| EP (1) | EP1350793A1 (no) |
| KR (1) | KR20040025881A (no) |
| CN (1) | CN1487936A (no) |
| AU (1) | AU2002221115A1 (no) |
| CA (1) | CA2431322A1 (no) |
| HU (1) | HUP0400683A2 (no) |
| NO (1) | NO20032614L (no) |
| PL (1) | PL362172A1 (no) |
| WO (1) | WO2002048142A1 (no) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6984653B2 (en) | 2001-10-05 | 2006-01-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof |
| TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| EP1667992B1 (en) * | 2003-09-19 | 2007-01-24 | Astrazeneca AB | Quinazoline derivatives |
| ATE539738T1 (de) * | 2003-10-08 | 2012-01-15 | Meiji Seika Pharma Co Ltd | Nichtkristalline antibakterielle zusammensetzung mit cefditoren-pivoxil |
| US7259262B2 (en) | 2003-10-24 | 2007-08-21 | Hoffmann-La Roche Inc. | Arylazole derivatives, their manufacture and use as pharmaceutical agents |
| JP4639745B2 (ja) * | 2004-01-19 | 2011-02-23 | 青葉化成株式会社 | 難固結性のタンパク質変性抑制剤粉末およびその使用方法 |
| US20080138437A1 (en) * | 2004-02-09 | 2008-06-12 | Shuji Sakuma | Antitumor Agent |
| CA2585659A1 (en) * | 2004-11-05 | 2006-06-22 | Cephalon, Inc. | Cancer treatments |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| WO2006087919A1 (ja) * | 2005-01-28 | 2006-08-24 | Takeda Pharmaceutical Company Limited | 難水溶性物質含有微細化組成物 |
| EP1872798B1 (en) * | 2005-04-06 | 2013-06-05 | Kabushiki Kaisha Sangi | Intestinal absorptive anti-tumor agent |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| CA2723989C (en) * | 2008-05-13 | 2017-04-25 | Astrazeneca Ab | Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline |
| US7749300B2 (en) * | 2008-06-05 | 2010-07-06 | Xerox Corporation | Photochemical synthesis of bimetallic core-shell nanoparticles |
| CN102164579B (zh) * | 2008-09-25 | 2014-10-15 | 赛福伦公司 | 苯达莫司汀的液体配制品 |
| CN102281877B (zh) * | 2009-01-15 | 2014-07-23 | 赛福伦公司 | 苯达莫司汀的游离碱形式 |
| ES2650608T3 (es) * | 2011-10-14 | 2018-01-19 | Array Biopharma, Inc. | Dispersión sólida |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| WO1996019239A1 (fr) * | 1994-12-21 | 1996-06-27 | Yamanouchi Pharmaceutical Co., Ltd. | Composition solide a solubilite et absorbabilite ameliorees |
| US6211215B1 (en) * | 1996-07-19 | 2001-04-03 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
-
2001
- 2001-12-11 HU HU0400683A patent/HUP0400683A2/hu unknown
- 2001-12-11 EP EP01270221A patent/EP1350793A1/en not_active Withdrawn
- 2001-12-11 KR KR10-2003-7007802A patent/KR20040025881A/ko not_active Application Discontinuation
- 2001-12-11 CN CNA018224318A patent/CN1487936A/zh active Pending
- 2001-12-11 PL PL01362172A patent/PL362172A1/xx not_active Application Discontinuation
- 2001-12-11 AU AU2002221115A patent/AU2002221115A1/en not_active Abandoned
- 2001-12-11 US US10/433,720 patent/US20040053972A1/en not_active Abandoned
- 2001-12-11 WO PCT/JP2001/010827 patent/WO2002048142A1/ja not_active Application Discontinuation
- 2001-12-11 CA CA002431322A patent/CA2431322A1/en not_active Abandoned
-
2003
- 2003-06-10 NO NO20032614A patent/NO20032614L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20040053972A1 (en) | 2004-03-18 |
| AU2002221115A1 (en) | 2002-06-24 |
| NO20032614D0 (no) | 2003-06-10 |
| HUP0400683A2 (hu) | 2004-06-28 |
| PL362172A1 (en) | 2004-10-18 |
| CN1487936A (zh) | 2004-04-07 |
| WO2002048142A1 (fr) | 2002-06-20 |
| EP1350793A1 (en) | 2003-10-08 |
| KR20040025881A (ko) | 2004-03-26 |
| CA2431322A1 (en) | 2002-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1524266T3 (da) | Farmaceutisk sammensætning | |
| FI20105657A (fi) | Farmaseuttisia koostumuksia | |
| AR028204A1 (es) | Composiciones farmaceuticas electrohiladas | |
| NO20025450L (no) | Ny farmasöytisk sammensetning | |
| ITMI20010748A0 (it) | Composizioni farmaceutiche | |
| DK1397364T3 (da) | Hidtil ukendte pyrrolderivater som farmaceutiske midler | |
| FI20011478A0 (fi) | Farmaseuttinen koostumus | |
| ITTO20010005A0 (it) | Formulazione farmaceutica. | |
| ITMI20001450A0 (it) | Nuova composizione farmaceutica | |
| NO20015175L (no) | Farmasöytisk sammensetning | |
| NO20032613D0 (no) | Farmasöytisk sammensetning som har en forbedret vannopplöselighet | |
| MXPA03001425A (es) | Compuestos farmaceuticos. | |
| NO20032614L (no) | Farmasöytisk sammensetning som har forbedret absorberbarhet | |
| IS7051A (is) | Lyfjasamsetningar | |
| NO20026123L (no) | Farmasöytiske sammensetninger | |
| NO20040860L (no) | Farmasoytisk sammensetning som innbefatter lumiracoxib | |
| FI20022128A (fi) | Farmaseuttinen koostumus | |
| NO20031095L (no) | Farmasoytiske sammensetninger | |
| DE60217390D1 (de) | Bicalutamid enthaltende pharmazeutische zusammensetzung | |
| FI4488U1 (fi) | Farmaseuttinen koostumus | |
| DE10291905D2 (de) | Pharmazeutische Zusammensetzung | |
| DK1313481T3 (da) | Farmaceutisk sammensætning, som omfatter kondenserede indolforbindelser | |
| DE10107261B4 (de) | Pharmazeutische Zusammensetzung | |
| MXPA03001857A (es) | Composicones medicinales. | |
| EE200200689A (et) | Ravimkoostised |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |